These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38956543)

  • 1. The EQ-5D-5L valuation study for Trinidad and Tobago.
    Bailey H; Jonker MF; Pullenayegum E; Rencz F; Roudijk B
    Health Qual Life Outcomes; 2024 Jul; 22(1):51. PubMed ID: 38956543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EQ-5D-3L valuation study for Bermuda: using an on-line EQ-VT protocol.
    Bailey H; Roudijk B; Brathwaite R
    Eur J Health Econ; 2024 Jul; ():. PubMed ID: 38982011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
    Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
    Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
    Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
    Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Direct Comparison Between Discrete Choice With Duration and Composite Time Trade-Off Methods: Do They Produce Similar Results?
    Roudijk B; Jonker MF; Bailey H; Pullenayegum E
    Value Health; 2024 Sep; 27(9):1280-1288. PubMed ID: 38843979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
    Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward Explicit Prioritization for the Caribbean: An EQ-5D Value Set for Trinidad and Tobago.
    Bailey H; Stolk E; Kind P
    Value Health Reg Issues; 2016 Dec; 11():60-67. PubMed ID: 27986200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EQ-5D-5L population norms and health inequalities for Trinidad and Tobago.
    Bailey H; Janssen MF; La Foucade A; Kind P
    PLoS One; 2019; 14(4):e0214283. PubMed ID: 31034491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets.
    Law EH; Pickard AS; Xie F; Walton SM; Lee TA; Schwartz A
    Med Decis Making; 2018 Nov; 38(8):968-982. PubMed ID: 30403577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
    Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
    Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. German Value Set for the EQ-5D-5L.
    Ludwig K; Graf von der Schulenburg JM; Greiner W
    Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EQ-5D-5L Value Set for Slovenia.
    Prevolnik Rupel V; Ogorevc M
    Pharmacoeconomics; 2023 Nov; 41(11):1515-1524. PubMed ID: 37341959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating an EQ-5D-Y-3L Value Set for China.
    Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.